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Rate of immune reconstitution directly correlates with the number of hematopoietic stem cells infused and is
particularly delayed in patients undergoing cord blood (CB) transplantation (CBT). Methods to increase the
number of CB natural killer (NK) cells have the potential to improve immune reconstitution after CBT. NK cells
are the ﬁrst lymphocyte population to recover after hematopoietic stem cells transplantation and are central
to preventing early relapse and infection. CB NK cells are low in number and are known to be incomplete in
maturation and require activation for effective function. Here, we report a clinically relevant ex vivo
expansion method that increases the number of activated CB NK cells. We report a multilog increase in NK
cell number when CB mononuclear cells are cocultured with IL-2 and IL-15. Furthermore, NK cells expressing
activating receptors and adhesion molecules responsible for cytotoxicity increased throughout culture,
whereas inhibitory receptor expression remained low. Additionally, cytotoxic function against various
malignancies was signiﬁcantly enhanced in cultured NK cells but not CD3þCD56þ cells. These data suggest
that ex vivo expansion and activation of CB NK cells is a clinically feasible and relevant approach to prevent
early infection and relapse after CBT.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Natural killer (NK) cells are part of the innate immune
system that eliminates malignant and virally infected cells
through cytolytic killing and cytokine secretion. The
receptors that regulate NK cell function may be categorized
on the basis of their ligand speciﬁcity for MHC class I (MHC-
I) and related molecules [1]. In humans, one of the most
important groups of receptors responsible for NK cell
function are killer cell immunoglobulin-like receptors
(KIRs). KIRs are expressed at the surface of NK cells and
recognize HLA class I molecules [2]. The KIR ligands
expressed on target cells, or lack thereof, determine the
response of NK cells, resulting in either tolerance or
cytolytic killing of the target. However, overall NK cell
responses are dependent on a balance of signals generated
through both activating and inhibitory receptors. Expres-
sion of various combinations of these NK cell receptors
creates a diverse repertoire of effector cells.dgments on page 48.
quests: Mari H. Dallas, MD, Department
nd Cellular Therapy, St. Jude Children’s
as Place, MS-321, Memphis, TN 38105.
ude.org (M.H. Dallas).
14.10.014
ty for Blood and Marrow Transplantation.NK cells play a crucial role in early immune reconstitution
after hematopoietic cell transplantation (HCT) because they
are the ﬁrst lymphocyte subset to recover [3,4]. Thus,
methods to increase the number of cord blood (CB) NK cells
have the potential to prevent early relapse, infection, and
graft-versus-host disease (GVHD), as well as facilitate
engraftment after cord blood transplantation (CBT) [5,6].
Studies have shown that CB contains a higher percentage of
NK cells than adult peripheral blood (PB) [7,8]. Although NK
cells in CB are reported to have lower cytotoxic function than
those found in PB, cytotoxicity can be signiﬁcantly increased
by activation with a cytokine cocktail, often containing IL-2
or IL-15 [7,9-14]. Alternatively, NK cell cytotoxic function
has also been augmented by the use of chimeric antigen
receptor or artiﬁcial antigen presenting feeder cells [15-18].
Yet cytolytic function of NK cells has typically only been
assessed by the use of the K562 cell line, a chronic myelog-
enous leukemia known to be NK cell sensitive. Determining
the cytotoxic potential of NK cells against other leukemias
and lymphomas is warranted.
In haploidentical HCT, selecting a donor based on KIR
ligand mismatch shows a signiﬁcant survival advantage.
However, the effect of KIR ligand mismatch in CBT remains
controversial. Two retrospective studies on the effects of KIR
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results. The Eurocord study showed a favorable effect of KIR
ligand mismatching on relapse incidence and leukemia-free
survival, whereas theMinneapolis study showed no effect on
these endpoints and a detrimental effect on incidence of
GVHD [19]. Although the KIR proﬁle is similar in both CB and
PB NK cells, studies have indicated that CB NK cells have
lower KIR expression than those found in PB [12]. Although
current studies have demonstrated that CB NK cells have
heterogeneous KIR proﬁles, most studies have focused on
freshly isolated NK cells [20]. Few studies have examined KIR
proﬁles in NK cells before and after culture [12-14]. Addi-
tional studies in the ﬁeld of NK cells, their receptors, and
their ligands may aid in determining the role of KIR ligand
mismatching after CBT.
With over 20,000 CBTs performed since 1988, CB is a
widely accepted alternative source of hematopoietic stem
cells for transplantation and has emerged as an accessible
source of NK cells that can be easily puriﬁed with the po-
tential for multilog fold expansion [11,21]. We isolated and
then expanded CB NK cells using IL-2, IL-15, and OKT3 cul-
ture conditions. NK cells were cocultured with CD56 leu-
kocytes, as they require the presence of other cells,
speciﬁcally dendritic cells, to proliferate [22]. Although
CD3þCD56þ cells are also expanded during culture, previous
studies have described conﬂicting results regarding their
cytotoxic potential [11,23]. In adult PB, NK-like T cells are
reported to be diverse and capable of cytotoxic function.
However, the T cell diversity of CB CD3þCD56þ cells has not
been well described. Here, we evaluate CB NK and
CD3þCD56þ cell cytotoxic function toward several leukemia
and lymphoma target cell lines, as well as examine activating
and inhibitory receptor proﬁles of these cells before and after
culture. Our results demonstrate that CB NK cells, but not
CD3þCD56þ cells, can be successfully expanded ex vivo to
become antitumor effector cells. Furthermore, we compare
the expression proﬁles of activating and inhibitory receptors
of CB NK cells to PB NK cells to determine whether the
changes in expression were unique to the cell source or a
result of the expansion method.MATERIALS AND METHODS
Isolation and Culture of CB Mononuclear Cells and PB Mononuclear
Cells
Culture conditions for the expansion of NK cells were optimized using
CB mononuclear cells (CBMCs). Peripheral blood mononuclear cells were
collected from healthy donors with approval from the institutional review
board and written informed consent from donors (St. Jude Children’s
Research Hospital Blood Donor Center, Memphis, TN). After ﬁcoll density
centrifugation using Ficoll-Paque Plus (GE Healthcare, Pittsburgh, PA) ac-
cording to the manufacturers instructions, 1  107 CBMCs and peripheral
blood mononuclear cells were set aside and the remaining cells were then
enriched for the CD56þ population using an AutoMACS CD56 microbead kit
(Miltenyi Biotech, Auburn, CA). As previously described, the enriched CD56þ
cells were then mixed at a 1:1 ratio with CD56 cells to permit NK cell
proliferation (ie, CB or PB MIX samples) [24]. CellGenix Stem Cell Growth
Medium (CellGenix, Portsmouth, NH) containing 5% human serum, 100 U/
mL penicillin, 100 mg/mL streptomycin, 500 IU/mL IL-2, 10 ng/mL IL-15 and
10 ng/mL OKT3. Media was changed 5 days after isolation using the above
mediawithout OKT3, and then every 3 days thereafter for up to 28 days after
isolation.Target Cell Line Culture
K562 (chronic myelogenous leukemia, CML), Jurkat (T cell acute
lymphoblastic leukemia), MV4-11 (mixed lineage leukemia, MLL), and
RS4:11 (MLL) cells were cultured in DMEM containing 10% FBS, 100 U/mL
penicillin and 100 mg/mL streptomycin. HDLM2 (Hodgkin’s lymphoma) cells
were cultured in DMEM containing 20% FBS and penicillin/streptomycin.
Target cells were split 1:10 every 3 days.Phenotypic Analysis by Flow Cytometry
Immunoﬂuorescence staining
Brieﬂy, cells were washed once with 2% FBS in PBS, blocked with human
FcR for 15 minutes, followed by 15 minutes staining using an antibody
cocktail or matching isotype control cocktail. Cells were then washed 3
times. Flow cytometry was performed using a Millipore Guava easyCyte 8HT
ﬂow cytometer with the Millipore InCyte 2.2.2 software (Millipore, Billerica,
MA). For the CD107a phenotypic panel, ﬂow cytometry was performed on a
BD FACSAria III using the BD FACSDiva 7.0 software (BD Biosciences). A
minimum of 30,000 events was collected and data was analyzed using
FlowJo 9.7 (Tree Star, Ashland, OR).
Natural killer cell phenotypic panel
NK (CD3CD14CD56þ) and CD3þCD56þ (CD3þCD14CD56þ) cell pro-
liferation during culture was evaluated by ﬂow cytometry for the expression
of CD3 PerCP-Cy5.5, CD45 FITC, and CD56 APC (BD Bioscience) and absence
of CD14 PE-Cy7 (BioLegend), CD19 PE, CD20 PE (BD Bioscience) on days 0, 7,
14, 21, and 28 after isolation.
Killer Ig-like receptor phenotypic panel
KIR phenotypic analysis of NK (CD3CD14CD45þCD56þ) and
CD3þCD56þ (CD3þCD14 CD45þCD56þ) cells by ﬂow cytometry was per-
formed on days 0, 14, and 21 after isolation. Samples were assessed for
expression of CD3 APC-Cy7, CD4 PerCP, CD8 PE, ITGAL/CD11a PE (BD Biosci-
ence), CD14 PE-Cy7 (BioLegend), CD45 FITC, CD56 APC, Fas receptor (FasR)/
CD95 PerCP-Cy5.5 (BD Bioscience), Fas ligand (FasL)/CD178 AlexaFluor488
(AbD Serotec, Raleigh, NC), DNAM1/CD226 FITC, 2B4/CD244 PE, TRAIL/
CD253 PE, NKG2D/CD314 PerCP-Cy5.5 (BD Bioscience), NKp30/CD337
PE-Cy5, NKp44/CD336 PE-Cy5, NKp46/CD335 PE-Cy5 (BeckmanCoulter,
Miami, FL), KIR2DL1/CD158a FITC/PE (R&D Systems, Minneapolis, MN),
KIR2DL2/3/CD158b FITC/PE, KIR3DL1/NKB1 FITC/PE (BD Bioscience), NKG2A/
CD159a PE (BeckmanCoulter), and NTBA/SLAMF6 FITC (R&D Systems).
CD107a phenotypic panel
NK (CD3CD14CD45þCD56þ) and CD3þCD56þ (CD3þCD14CD45þCD
56þ) cells were analyzed by ﬂowcytometry for the expression of CD3 BV605,
CD4 BV786, CD8 BV510, CD45 FITC, CD56 APC, CD107a PE (BD Bioscience),
and CD14 PE-Cy7 (BioLegend).
Cytotoxicity Coculture Assays
BADTA cytotoxicity assay
Cytotoxicity of samples was assessed on the day of isolation and at days
7, 14, and 21 after isolation against both NK cellesensitive (K562, Jurkat) and
NK celleresistant (MV4-11, RS4;11, HDLM2) target cancer cell lines. Target
cells were labeled with the DELFIA BADTA reagent according to manufac-
turer’s instructions (PerkinElmer, Waltham, MA), washed, and then cocul-
tured with effector cell samples (CBMC or MIX) at a ratio of 10:1 (effector to
target) for 2 hours at 37C. Each coculture was performed in triplicate.
Supernatants were then incubated with the DELFIA Europium detection
solution (PerkinElmer), and ﬂuorescence was measured on aWallac Victor 2
Counter Plate Reader (PerkinElmer). Cytotoxicity was calculated using the
following formula: percent cell lysis ¼ 100  ([experimental release e
spontaneous release]/[maximal release e spontaneous release]).
CD107a assay
Expression of CD107a on the surface of both NK and CD3þCD56þ cells
was assessed at day of isolation and at days 14 and 21 after coculture with
the above target cancer cell lines. 2  105 effector cells were cocultured with
or without 2 105 target cells per well in a 96-well plate for 2 hours at 37C.
Cells were then stained with the above CD107a phenotypic panel and
analyzed by ﬂow cytometry.
Statistical Analysis
Data are presented as the mean the standard error of the mean (SEM).
Statistical signiﬁcance was assessed using a 2-tailed nonparametric t-test
when comparing 2 groups, or a 1-way ANOVA using the Tukey’s post hoc
test when comparing more than 2 groups (Graphpad Prism 5.0, La Jolla, CA).
P values below .05 were considered statistically signiﬁcant.
RESULTS
CB NK and CD3þCD56þ Cells Proliferate Ex Vivo
CBMC and CB MIX samples were cultured for up to
28 days after isolation. We found that both NK and
CD3þCD56þ cell populations within each sample type had a
signiﬁcant multilog-fold increase up to 21 days of culture as
determined by ﬂow cytometry (Figure 1A). Samples cultured
AB
Figure 1. CB NK and CD3þCD56þ cells proliferate ex vivo. Freshly isolated
CBMC or CB CD56þ enriched (MIX) cells were cultured for 21 days with IL-2,
IL-15 and OKT3. NK (- - -; CBMC D/MIX ☐) and CD3þCD56þ cell (; CBMC
A/MIX ) proliferation was then assessed for phenotypic expression of CD3þ/
CD14CD19CD20CD45þCD56þ by ﬂow cytometry (A) (n ¼ 10). The fre-
quency of CD3þCD56 T cells (– - –; CBMC  /MIX 5) CD3þCD56þ cells (;
CBMC A/MIX ) and NK cells (- - -; CBMC D/MIX ☐) within the lymphocyte
population was also assessed during culture (B) (n ¼ 8). Depicted are
means  SEM. *P < .05, **P < .01.
Figure 2. Enriched CB CD56þ cell samples are more cytotoxic to K562 after
culture. CB samples were assessed for cytotoxic function towards K562, a CML
cell line sensitive to NK cells, using a BADTA cytotoxicity assay. Samples were
cocultured for 2 hours with K562 at effector to target ratios of 10:1. Samples
were performed in triplicate. Depicted are means  SEM (n ¼ 8). Signiﬁcance
was assessed by comparing cultured samples to freshly isolated, day 0 sam-
ples, or between groups as indicated. *P < .05, **P < .01, ***P < .001.
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fold decrease between days 21 and 28 (data not shown),
indicating that the optimal culturing period for CB NK and
CD3þCD56þ cells is between 0 and 21 days after isolation.
Although CD3þCD56þ cells (solid lines) had a greater fold
increase than NK cell (broken lines) populations, we deter-
mined that overall cell numbers were lower for CD3þCD56þ
cells than for NK cells. When examining overall frequencies
of the lymphocyte population, NK cells were at a greater
frequency than the CD3þCD56þ cell population in both the
CBMC and CB MIX populations before and after culture
(Figure 1B).
Enriched CB CD56þ Cell Samples Are More Cytotoxic to
K562 after Culture
After establishing culture conditions that signiﬁcantly
expand NK cells, we next examined their function by
assaying cytotoxic function toward K562, a CML and NK
cell-sensitive target cell line. Cytolytic potential of samples
were assessed at day of isolation, as well as on days 7, 14, 21,
and 28, by coculturing samples (effector) with K652 (target)
at a variety of effector to target ratios, including 40:1, 20:1,
10:1, 5:1, and 1:1 (Figure 2, Supplementary Figure 1). Both
CBMC and CB MIX samples were not cytotoxic on the day of
isolation. However, CB MIX samples (white bars) were
signiﬁcantly more cytotoxic at days 7 to 21 when compared
with day of isolation, whereas CMBC samples (gray bar)
were only signiﬁcantly cytotoxic after 14 to 21 days of cul-
ture (Figure 2). Furthermore, the CB MIX samples were
signiﬁcantly more cytotoxic than the CBMC samples
throughout culture. After 21 days of culture, cytotoxicity
decreased between days 21 and 28 (Supplementary
Figure 1), which conﬁrmed that optimal culturing time
period is up to 21 days.CB CD56þ Cells Expressing Activating Receptors Increase
during Culture
Cytotoxicity of NK cells is inﬂuenced by the regulation of
various activating and inhibitory receptors and ligands. Thus,
we performed an extensive analysis by ﬂow cytometry to
determine receptor and ligand expression during culture. NK
cell receptors, including activating, coactivating, inhibitory,
and adhesion receptors, as well as other receptors respon-
sible for cytotoxicity, were evaluated in both CB and PB NK
and CD3þCD56þ cell populations during culture.
We ﬁrst examined activating receptor expression on the
day of isolation and on days 14 and 21 in culture for CB and
PB. The percent of NK and CD3þCD56þ cells expressing
NKp30/CD337, NKp44/CD336, and NKp46/CD335 (white
bars) was very low for freshly isolated CB samples
(Figure 3A-C). However, there was a signiﬁcant increase in
the percent of NK and CD3þCD56þ cells in all CB samples
after 14 to 21 days of culture (black, gray), that expressed
natural cytotoxicity receptors, NKp30/CD337, and NKp44/
CD336 and NKG2D/CD314 (Figure 3A,B,D, left panels),
whereas NKp46/CD335 (Figure 3C) was expressed in signif-
icantly more CB NK and CD3þCD56þ cells at day 14 (black).
We also found that the number of NK and CD3þCD56þ cells
expressing these receptors was signiﬁcantly higher in CB
MIX samples compared with CBMC cultures and the percent
of NK cells expressing activating receptors was signiﬁcantly
more than CD3þCD56þ cells. Previously, Rujkijyanont et al.
showed that ex vivo expansion of PB NK and CD3þCD56þ
cells resulted in increased expression of activating receptors
but not inhibitory KIRs [24]. Here, we report a similar in-
crease in expression of activating receptors during culture in
CB samples, with a greater percent increase in CB compared
with PB samples during culture.
Activating Coreceptor and Adhesion Receptor Expression
in CD56þ Cells during Culture
Concurrently, the expression of the activating coreceptors
NTBA/SLAMF6 and 2B4/CD244 were also explored in CB and
PB. Unlike the activating receptors, NTBA/SLAMF6 was
expressed in NK and CD3þCD56þ cells from freshly isolated
CB and PB; however, it was signiﬁcantly lower in CB than PB
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Figure 3. CB CD56þ cells expressing activating receptors increase during culture. NK and CD3þCD56þ cells from CB and PB were gated on CD3þ/CD14CD45þCD56þ
expression then evaluated for expression of activating receptors NK/CD337 (A), NKp44/CD336 (B), NKp46/CD335 (C) and NKG2D/CD314 (D) on days 0, 14, and 21.
Depicted are means  SEM (CBMC, n ¼ 8; MIX/peripheral blood mononuclear cells/PB MIX, n ¼ 4). Signiﬁcance was assessed by comparing cultured samples to
freshly isolated, day 0 samples or between groups as indicated. *P < .05, **P < .01, ***P < .001.
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decreased between day 0 and 14 in culture but increased
again between days 14 and 21 in all CB samples, whereas the
percent of PB CD56þ cells expressing NTBA/SLAMF6 signiﬁ-
cantly declined during culture (Figure 4A). Additionally, 2B4/
CD244 expression did not signiﬁcantly change during culturefor CB samples, although the majority of PB CD56þ cells
expressed 2B4/CD244 on day 0, which then signiﬁcantly
declined during culture (Figure 4B).
As adhesion receptors are important molecules that
contribute to lytic synapse formation and subsequent
cytolytic function, we examined both ITGAL/CD11a and
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Figure 4. Activating coreceptor and adhesion receptor expression in CD56þ Cells during culture. NK and CD3þCD56þ cells from CB and PB were gated on CD3þ/
CD14CD45þCD56þ expression then evaluated for expression of activating coreceptors, NTBA/SLAMF6 (A) and 2B4/CD244 (B), and adhesion molecules, ITGAL/CD11a
(C), and DNAM1/CD226 (D), on days 0, 14, and 21. Depicted are means  SEM (CBMC, n ¼ 8; MIX/peripheral blood mononuclear cells/PB MIX, n ¼ 4). Signiﬁcance was
assessed by comparing cultured samples to freshly isolated, day 0 samples or between groups as indicated. *P < .05, **P < .01, ***P < .001.
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of CD56þ cells expressed ITGAL/CD11a (Figure 4C) in both
CB and PB, independent of culture. In contrast, freshly iso-
lated CB samples had very little expression of DNAM1/
CD226 in either NK or CD3þCD56þ cells compared with PB
samples (Figure 4D). However, the percent of CD56þ cells
that expressed DNAM1/CD226 on days 14 and 21 was
signiﬁcantly increased compared with day 0 CB samples,
whereas the majority of PB samples expressed DNAM1/CD226 throughout culture. Furthermore, more CD3þCD56þ
cells expressed DNAM1/CD226 than NK cells in the CBMC
samples.
CD56þ Cells Express Inhibitory Receptors during Culture
Cytotoxic function is due to a combination of activating
and inhibitory receptor signaling. Therefore, we assessed KIR
inhibitory receptors on the CD56þ subsets of our samples.
The percent of CD56þ cells that expressed KIR2DL/1/CD158a,
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Figure 5. CD56þ cells express inhibitory receptors during culture. NK and CD3þCD56þ cells from CB and PB were gated on CD3þ/CD14CD45þCD56þ expression
then evaluated for expression of inhibitory KIR, KIR2DL1/CD158a (A), KIR2DL2/3/CD158b (B), KIR3DL1/NKB1 (C), and NKG2A/CD159a (D), on days 0, 14, and 21.
Depicted are means  SEM (CBMC, n ¼ 8; MIX/peripheral blood mononuclear cells/PB MIX, n ¼ 4). Signiﬁcance was assessed by comparing cultured samples to
freshly isolated, day 0 samples or between groups as indicated. *P < .05, **P < .01, ***P < .001.
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all CB NK cells and both CB and PB CD3þCD56þ cells, whereas
the percent of PB NK expressing these KIRs was much higher
(Figure 5A-C). Unlike the activating receptors, cultured CB
samples only showed a slight, but insigniﬁcant, increase in
the percent of NK and CD3þCD56þ cells that express these
inhibitory receptors. In both CBMC and CB MIX samples,
there was a higher percentage of NK cells that expressedKIR2DL2/3/CD158b than CD3þCD56þ cells (Figure 5B). In
contrast, the percent of CD56þ cells that express NKG2A/
CD159a was much higher than the latter inhibitory KIR
for both CB and PB samples. Although there was no statisti-
cal difference in the percent of CB cells that expressed
NKG2A/CD159a on the day of isolation or through culture,
this inhibitory receptor was expressed in signiﬁcantly more
NK cells than in CD3þCD56þ cells, for both CBMC and CB MIX
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Figure 6. Expression of FasR, FasL and TRAIL on CD56þ cells during culture. NK and CD3þCD56þ cells from CB and PB were gated on CD3þ/CD14CD45þCD56þ
expression then evaluated for expression of additional receptors, FasR/CD95 (A), FasL/CD178 (B), and TRAIL/CD253 (C), on days 0, 14 and 21. Depicted are
means  SEM (CBMC, n ¼ 8; MIX/peripheral blood mononuclear cells/PB MIX, n ¼ 4). Signiﬁcance was assessed by comparing cultured samples to freshly isolated,
day 0 samples or between groups as indicated. *P < .05, **P < .01, ***P < .001.
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percent of CD56þ cells that expressed NKG2A/CD159a than
the CBMC samples.Expression of FasR, FasL, and TRAIL on CD56þ Cells
during Culture
FasR/CD95 was expressed in the majority of NK and
CD3þCD56þ cells in freshly isolated PB samples, although
only a very small percentage of CB CD56þ cells expressed
FasR/CD95 at day 0. However, signiﬁcantly more CB samples
expressed FasR after days 14 and 21 in culture compared
with day 0 (Figure 6A). FasL/CD178, which may contribute to
target cell apoptosis, was expressed in only a small percent of
CB and PB cells and did not signiﬁcantly change during cul-
ture (Figure 6B). TRAIL/CD253, another apoptosis-inducing
ligand, was expressed in a small subset of NK and
CD3þCD56þ cells in CB and PB (Figure 6C); however, only CB
MIX samples had a signiﬁcant increase in the percent of cells
expressing this ligand at day 14 (black).Ex Vivo Cultured CB NK Cells Are More Cytotoxic than
CD3þCD56þ Cells Toward Leukemia/Lymphoma Cell Lines
After identifying different receptors that could contribute
to the increase in cytotoxic function against the NK
cellesensitive line, K562, we then examined whether these
cultured samples also had the ability to lyse a variety of
different leukemia and lymphoma cell lines. Cytolytic po-
tential of samples were assessed at day of isolation, as well as
at days 14 and 21 by coculturing samples (effector) with
K652, Jurkat (NK cell sensitive), MV4-11, RS4;11, and HDLM2
(NK cell resistant) cell lines. Samples were cocultured at a
ratio of 10:1, which was previously determined, as shown in
Figure 2, as a moderate ratio that would identify statistical
signiﬁcance while conserving sample. Cultured CBMC sam-
ples had a signiﬁcant increase in cytotoxic function against
K562, as previously described, but also against MV4-11, NK-
resistant cells, after 21 days of culture (Figure 7A). In
contrast, when we assayed the cytolytic potential of the CB
MIX samples that have an enriched CD56þ population, there
was a drastic increase in cytotoxic function against all K562,
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Figure 7. Ex vivo cultured CB NK cells are more cytotoxic than CD3þCD56þ cells toward leukemia/lymphoma cell lines. Cytotoxicity of samples was assessed at day of
isolation as well as at days 14 and 21 using a BADTA assay. Several cancer cell lines were used as target cells, including K562 (CML) and Jurkat (T cell acute
lymphoblastic leukemia), which are considered NK cellesensitive cell lines, and the MV4-11 (MLL), RS4; 11 (MLL/acute lymphoblastic leukemia) and HDLM2
(Hodgkin’s lymphoma) cell lines, which are considered NK celleresistant. CBMC (A) or CB MIX (B) samples were cocultured for 2 hours at an effector to target ratio of
10:1. Day 14 CBMC samples were also sorted into NK (CD3CD14CD56þ) and CD3þCD56þ (CD3þCD14CD56þ) or non-NK (CD56) cell groups before coculturing at a
ratio of 5:1 with the target cells (C). Samples were performed in triplicate. Depicted are means  SEM. Signiﬁcance was assessed by comparing cultured samples to
freshly isolated, day 0 samples or between groups as indicated. *P < .05, ***P < .001.
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(Figure 7B, black and gray). We were not able to attain
cytotoxic function against RS4;11 or HDLM2, which are
known to be NK cell resistant.
As there was a signiﬁcant increase in the cytotoxicity of
samples enriched with C56þ cells, CB NK and CD3þCD56þ
cells were then sorted and assessed for cytotoxicity. CB
samples were cultured for 14 days, and then NK, CD3þCD56þ,
and non-NK cells were sorted and cocultured with BADTA-
labeled target cell lines at a ratio of 5:1. A lower ratio was
used to test the NK and CD3þCD56þ cells against all target
cell lines. Results of this assay demonstrated that NK cells
and not CD3þCD56þ cells were responsible for cytotoxic
function, as they were signiﬁcantly more cytotoxic than
either the CD3þCD56þ cells or non-NK cells against K562 and
Jurkat cells (Figure 7C).
Expression of Surface CD107a after Target Cell Coculture
CD107a is a marker for degranulation when expressed on
the surface of NK and T cell subsets and is an alternative
indicator of cytotoxic function. To further verify NK cell
cytolytic potential in our samples, we also examined CD107a
surface expression on CB NK and CD3þCD56þ cells after
coculture with the target cells. On day of isolation, there was
no difference in the number of cells expressing CD107a be-
tween untreated or cocultured cells for either NK or
CD3þCD56þ cells (Figure 8A). However, after culturing for 14
and 21 days, there were signiﬁcantly more CB NK cells that
expressed surface CD107a when cocultured with K562
(slanted stripe), Jurkat (gray), MV4-11 (light gray), and
RS4;11 (horizontal stripe) than untreated NK cells (black)
(Figure 8B,C). In addition, NK cells had the highest percent
expression of CD107a compared with CD3þCD56þ cells,
which expressed signiﬁcantly less CD107a after coculture
(Figure 8B,C). Only a small percent of CD3þCD56þ cellsoverall expressed CD107a, independent of either time in
culture or coculture with target cells. These CD107a results
further conﬁrm our sorted cytotoxicity assay that only CB NK
cells had cytolytic potential.DISCUSSION
Here we report that NK cells can be successfully prolifer-
ated ex vivo from CB to become functional effector cells
against leukemia. We employed the ex vivo expansion
method ﬁrst developed by Rujkijyanont et al. for PB-derived
NK cells. We utilized IL-2, IL-15, and the monoclonal CD3
antibody OKT3 in our culture media that led to a signiﬁcant
multilog-fold increase in NK cell proliferation after 21 days in
culture for both CBMC and CB MIX samples [24]. We also
showed a signiﬁcant increase in CD3þCD56þ cell proliferation
during this time in both sample types. Our culture conditions
show that NK cells can be feasibly expanded from either
CBMC cells or by enriching for CD56þ, which would decrease
material required for ex vivo expansion in clinical settings.
Upon initial investigation as to the cytotoxic function of
the cultured samples, all samples were signiﬁcantly cytotoxic
towards K562 cells at effector to target ratios of 40:1 down to
5:1. However, as previously described, freshly isolated CB
samples did not exhibit cytotoxic function [7,9,10]. We also
determined that the CB MIX samples containing an enriched
CD56þ population were more cytotoxic than the CBMC
samples, suggesting that the number of NK cells correlated
with the cytotoxic potential of the sample. Although the
frequency of NK cells in the lymphocyte population also
increased in both sample types during culture, they did not
become the majority lymphocyte population. This result
suggests that not only did the increase in CD56þ cells affect
sample cytotoxicity, but also that the NK cell population was
activated by the culture method.
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Figure 8. Expression of surface CD107a after target cell coculture. Cytotoxicity of CB sampleswas assessed at dayof isolation (A) aswell as at days 14 (B) and 21 (C). CBMC
samples were cocultured 1:1with K562, Jurkat, MV4-11, RS4;11, or HDLM2 cells, or cultured alone (UTX) for 2 hours. Samples were then analyzed by ﬂowcytometry. CB
NK and CD3þCD56þ cells were gated on CD3þ/CD14 CD45þCD56þ expression then evaluated for surface expression of CD107a. Depicted are means  SEM (n ¼ 12).
Signiﬁcance was assessed by comparing cocultured samples to untreated samples or between groups as indicated. *P < .05, **P < .01, ***P < .001.
S.L. Tomchuck et al. / Biol Blood Marrow Transplant 21 (2015) 39e49 47As cytotoxicity for all the samples signiﬁcantly
increased throughout culture, we examined the NK cell
receptor expression proﬁles of samples before and afterculture. In contrast to the ﬁndings by Ayello et al., we
observed a signiﬁcant upregulation in the number of both
CB NK and CD3þCD56þ cells that express the activating
S.L. Tomchuck et al. / Biol Blood Marrow Transplant 21 (2015) 39e4948receptors NKp30/CD337, NKp44/CD336, NKp46/CD335, and
NKG2D/CD314 during culture [23]. Corresponding to the
activating receptors, more CB NK and CD3þCD56þ cells also
expressed DNAM1/CD226 after culture, whereas the ma-
jority of these cells expressed ITGAL/CD11a. When
surveying inhibitory KIR, we found that only a small
number of CB NK and CD3þCD56þ cell express KIR2DL/1/
CD158a, KIR2DL2/3/CD158b, or KIR3DL1/NKB1, which did
not dramatically change by culture. However, many more
CB CD56þ cells expressed the inhibitory NKG2A/CD159a,
yet its expression was unchanged during culture. These
results also conﬂict with the Ayello et al. ﬁndings, which
reported an increase of inhibitory receptors on CD3þCD56þ
cells and a decrease of these receptors on NK cells [23].
However, this discrepancy may be due not only to the
cytokine cocktail used but also to the culture period, which
was only 7 days versus our 14 to 21-day period. Yet, our
ﬁndings show similar trends as the Rujkijyanont et al.
study of PB-derived NK cells, which utilized the same
culture methods [24]. This study found that CD56þ cells
from PB also had an increase in activating receptor
expression but not in inhibitory KIR expression after cul-
ture that resulted in an activating, cytotoxic phenotype
[24]. CB NK cells, similar to PB NK cells, had a signiﬁcant
increase in activating receptors during culture. However,
there were unique differences between the 2 NK sources.
The activating coreceptors and adhesion receptor expres-
sion (NTBA/SLAMF6 and DNAM/CD226) were noticeably
lower in CB compared with in PB. Furthermore, the lower
expression of these receptors in CB samples compared with
PB samples after culture suggests that this may be a
characteristic inherent to the NK cell source rather than
due to the expansion method.
Our phenotypic proﬁles coincided with our K562 cyto-
toxicity results. When cytotoxic function was increased,
there was also a signiﬁcant increase in adhesion molecules
and activating receptor expression and a relatively lower
level of inhibitory KIR expression. These results are encour-
aging because they demonstrate that the cells being cultured
are not hyporesponsive, which is often found in NK cells that
express high levels of activating receptors but lack inhibitory
receptors [25-27]. We also examined other receptors that
contribute to cell cytotoxicity but found that neither NK nor
CD3þCD56þ cells have high expression of either TRAIL/
CD253 or the FasL/CD178, which could also mediate cytolytic
function. This indicates that the cytotoxicity of either CB NK
or CD3þCD56þ cells may be predominantly granzyme and
perforin dependent.
After determining the receptor proﬁles of both cultured
CB NK and CD3þCD56þ cells, we then evaluated the cyto-
toxic potential against a combination of leukemia and
lymphoma cell lines that are either NK cell sensitive or
resistant. At a 10:1 effector to target ratio, CBMC samples
had moderate cytotoxicity toward K562 and Jurkat (NK cell
sensitive) and MV4-11 (NK cell resistant) cell lines. In
contrast, the CB MIX samples had signiﬁcantly more
cytotoxicity toward these 3 cell lines. Again, we conﬁrmed
the indication that increased CD56þ cell numbers corre-
lated with a greater cytotoxic potential. Also of note, our
samples had the ability to lyse one of the NK celleresistant
cell lines, MV4-11, which is MLL rearranged, and FLT-3
positive, which is promising for both in vivo and clinical
studies.
Up to this point, our cytotoxic function studies have only
assayed the samples as a whole. We demonstrated that bothCB NK and CD3þCD56þ cell populations have signiﬁcantly
proliferated in culture and that both cell types express the
necessary receptor proﬁles needed for cytolytic function.
However, we wanted to identify if either subset, or poten-
tially both subsets, were carrying out this cytotoxic
response. Thus, we sorted our samples into CB NK,
CD3þCD56þ, and non-NK (CD56) groups and repeated our
cytotoxicity studies with our 5 target cell lines. We also
monitored degranulation using surface expression of
CD107a on both CB NK and CD3þCD56þ cell subsets after
coculture with the target cells. CB NK cells had signiﬁcantly
more CD107a on their surface after coculture and only NK
cells were able to lyse our target cells. In contrast, CB
CD3þCD56þ cells had lower CD107a expression, suggesting
less degranulation, and failed to have a cytolytic response.
These data conﬁrm that only the CB NK cells have cytotoxic
potential. These results also suggest that although cultured
CB CD3þCD56þ cells have the receptors and adhesion mol-
ecules necessary to yield a cytolytic response, they are un-
able to do so.
The lack of CB CD3þCD56þ cell cytolytic potential may
be due to several factors [28]. It was previously described
that CB CD3þCD56þ cells are not as potent as CB NK cells
[29]. Recent studies of NKT cells of either the T cell re-
ceptor (TCR) ab or gd lineage in CB have been reported
but the function has not been well described [30]. If in
fact the CD3þCD56þ cells are TCRgd, they may not have
robust cytotoxic potential but other effector functions
[31]. If the CD3þCD56þ cells are TCRab, they may be non-
CD1d restricted, as the majority of these cells were found
to be CD8þ (data not shown) or MHC class restricted or
possess degenerate TCRab receptors. Future studies will
examine the proliferation and characterization of these CB
CD3þCD56þ cell by performing a single-cell PCR assay to
determine the type(s) of CD3þCD56þ cells present in
culture.
Currently, clinical trials are utilizing PB NK cells in com-
bination with HCT with beneﬁcial results [32,33]. Our study
has determined that CB NK cells can also be feasibly propa-
gated ex vivo for potential use in a clinical setting and that
they maintain cytotoxic function through 21 days of culture.
We intend to expand upon these studies by investigating the
function of these cells in an in vivo mouse model to deter-
mine if these cells facilitate engraftment and survival after a
CBT and/or have a graft-versus-leukemia effect in a mouse
leukemia model. As CBT numbers rise, the ability to decrease
GVHD, delayed immune reconstitution, infection, and
relapse is of critical importance. The use of CB NK cells in
combination with CBT may be 1 method to decrease these
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